ALUMIS INC. - COMMON STOCK

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 Jan 2026 16:05:00 By Nasdaq GlobeNewswire

Alumis Announces Pricing of Upsized Public Offering of Common Stock

07 Jan 2026 22:52:42 By Nasdaq GlobeNewswire

Alumis Announces Proposed Public Offering of Common Stock

06 Jan 2026 16:12:10 By Nasdaq GlobeNewswire

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

06 Jan 2026 07:00:00 By Nasdaq GlobeNewswire

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

05 Jan 2026 17:00:00 By Nasdaq GlobeNewswire

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

13 Nov 2025 16:15:00 By Nasdaq GlobeNewswire

Alumis to Participate in Upcoming November Investor Conferences

04 Nov 2025 08:00:01 By Nasdaq GlobeNewswire

Alumis to Participate in Upcoming September Investor Conferences

29 Aug 2025 07:00:00 By Nasdaq GlobeNewswire

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

13 Aug 2025 16:05:00 By Nasdaq GlobeNewswire

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

24 Jul 2025 07:30:00 By Nasdaq GlobeNewswire

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

14 Jul 2025 16:05:00 By Nasdaq GlobeNewswire

Alumis to Present at the Jefferies Global Healthcare Investor Conference

29 May 2025 16:15:56 By Nasdaq GlobeNewswire

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

29 May 2025 07:55:00 By Nasdaq GlobeNewswire

Alumis Completes Merger with ACELYRIN

21 May 2025 09:10:51 By Nasdaq GlobeNewswire

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

14 May 2025 16:05:00 By Nasdaq GlobeNewswire

Alumis Stockholders Approve Merger with ACELYRIN

13 May 2025 13:00:00 By Nasdaq GlobeNewswire

Alumis and ACELYRIN Announce Amended Merger Agreement

21 Apr 2025 06:30:00 By Nasdaq GlobeNewswire

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

04 Apr 2025 16:34:51 By Nasdaq GlobeNewswire

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

25 Mar 2025 02:30:00 By Nasdaq GlobeNewswire

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

19 Mar 2025 16:05:00 By Nasdaq GlobeNewswire